my guess - they are hoping to use outcomes in specific populations as a marketing tool because they don't think the combo is likely to generate anything better clinically from the first generation of all orals
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.